Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Jiejing Group is a prominent Chinese biotechnology company specializing in the deep processing of seaweed for various industrial and healthcare applications. Established in 1968 and headquartered in Rizhao, the company is a global leader in the production of alginates, fucoidan, and other marine-derived polysaccharides. Their healthcare portfolio includes pharmaceutical-grade alginates used as excipients and in advanced wound care products, as well as fucoidan-based nutritional supplements. Jiejing Group maintains rigorous quality standards, including GMP certifications, to serve the global pharmaceutical, food, and cosmetic markets. The company's research and development efforts focus on expanding the therapeutic and functional uses of marine resources to improve human health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Jiejing Group.